Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.58 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17061886 | 1.00 | SCN9A (0.58) | SCN9APDE2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17061883 | 1.00 | SCN9A (0.58) | SCN9APDE2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16759210 | 0.93 | SCN9A (0.58) | SCN9APDE2A | |
| SCHEMBL16759208 | 0.93 | SCN9A (0.58) | SCN9APDE2A | |
| SCHEMBL17069306 | 0.92 | SCN9A (0.57) | SCN9APDE2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16759342 | 0.91 | SCN9A (0.51) | SCN9APDE2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16759339 | 0.91 | SCN9A (0.51) | SCN9APDE2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL21075157 | 0.91 | SCN9A (0.56) | SCN9APDE2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17061816 | 0.90 | SCN9A (0.62) | SCN9A | |
| SCHEMBL16759129 | 0.90 | SCN9A (0.62) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10125098-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180265465-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885PDE2A 411/4885SMN1; SMN2 2803/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | SCN9A 2337/4885PDE2A 411/4885SMN1; SMN2 2803/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885PDE2A 411/4885SMN1; SMN2 2803/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | SCN9A 2337/4885PDE2A 411/4885SMN1; SMN2 2803/4885 |
| US-20180265465-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885PDE2A 411/4885SMN1; SMN2 2803/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SCN9A 1605/4885PDE2A 573/4885SMN1; SMN2 2483/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | SCN9A 1669/4885PDE2A 444/4885SMN1; SMN2 2148/4885 |
| US-10125098-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | SCN9A 2337/4885PDE2A 411/4885SMN1; SMN2 2803/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | SCN9A 505/4885PDE2A 1204/4885SMN1; SMN2 2593/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885PDE2A 411/4885SMN1; SMN2 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.